HPC
NVO

HM Payson & Co’s Novo Nordisk NVO Stock Holding History

HM Payson & Co’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$102K Buy
2,131
+925
+77% +$39.7K ﹤0.01% 563
2026
Q1 		$44.3K Sell
1,206
-1,019
-46% -$48.3K ﹤0.01% 710
2025
Q4 		$113K Sell
2,225
-293
-12% -$15K ﹤0.01% 533
2025
Q3 		$140K Sell
2,518
-346,003
-99% -$20.3M ﹤0.01% 501
2025
Q2 		$24.1M Buy
348,521
+341,480
+4,850% +$23.2M 0.38% 56
2025
Q1 		$489K Buy
7,041
+2,600
+59% +$215K 0.01% 286
2024
Q4 		$382K Buy
4,441
+316
+8% +$34.2K 0.01% 317
2024
Q3 		$491K Buy
4,125
+150
+4% +$20K 0.01% 287
2024
Q2 		$567K Buy
3,975
+105
+3% +$13.9K 0.01% 260
2024
Q1 		$497K Sell
3,870
-56
-1% -$6.67K 0.01% 287
2023
Q4 		$406K Hold
3,926
– – 0.01% 294
2023
Q3 		$357K Hold
3,926
– – 0.01% 300
2023
Q2 		$318K Sell
3,926
-28
-0.7% -$2.29K 0.01% 312
2023
Q1 		$315K Buy
3,954
+28
+0.7% +$1.99K 0.01% 309
2022
Q4 		$266K Buy
3,926
+56
+1% +$3.28K 0.01% 328
2022
Q3 		$193K Sell
3,870
-4
-0.1% -$214 0.01% 368
2022
Q2 		$216K Buy
3,874
+4
+0.1% +$222 0.01% 362
2022
Q1 		$215K Hold
3,870
– – ﹤0.01% 387
2021
Q4 		$217K Sell
3,870
-76
-2% -$4.12K ﹤0.01% 387
2021
Q3 		$189K Hold
3,946
– – ﹤0.01% 396
2021
Q2 		$165K Buy
3,946
+410
+12% +$15.9K ﹤0.01% 415
2021
Q1 		$119K Sell
3,536
-576
-14% -$20.5K ﹤0.01% 461
2020
Q4 		$144K Buy
4,112
+3,312
+414% +$114K ﹤0.01% 432
2020
Q3 		$28K Sell
800
-4,000
-83% -$133K ﹤0.01% 675
2020
Q2 		$157K Sell
4,800
-1,100
-19% -$35.1K 0.01% 376
2020
Q1 		$178K Buy
5,900
+400
+7% +$11.9K 0.01% 339
2019
Q4 		$159K Hold
5,500
– – 0.01% 422
2019
Q3 		$142K Hold
5,500
– – 0.01% 438
2019
Q2 		$140K Buy
+5,500
New +$136K 0.01% 448
2016
Q3 		– Sell
-8,190
Closed -$221K – 328
2016
Q2 		$221K Buy
+8,190
New +$225K 0.01% 303

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

HM Payson & Co's NVO Position: Q2 2026 in Review

HM Payson & Co increased its Novo Nordisk (NVO) stake by 77% in Q2 2026, buying an estimated $39.7K and bringing the position to 2,131 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #563.

HM Payson & Co first reported a position in NVO in Q2 2016 and has held it in 30 quarters since. The position peaked at $24.1M in Q2 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • HM Payson & Co held 2,131 shares of Novo Nordisk worth $102K as of Q2 2026.
  • HM Payson & Co bought 925 Novo Nordisk shares in Q2 2026, an estimated $39.7K.
  • Novo Nordisk made up ﹤0.01% of HM Payson & Co's portfolio in Q2 2026, its #563 holding.
  • HM Payson & Co first reported a position in Novo Nordisk in Q2 2016 and has held it in 30 quarters since.
  • HM Payson & Co's Novo Nordisk position peaked at $24.1M in Q2 2025.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on HM Payson & Co's 13F filing for Q2 2026, filed 17 Jul 2026.